Worldwide Distribution Agreement for DNA Microarrays
News Sep 14, 2005
Acacia Research Corporation has announced that its CombiMatrix group has entered into a global distribution agreement with VWR International, Inc. to distribute CustomArrays™and CatalogArrays™ for CombiMatrix.
CombiMatrix's CustomArray platform consists of DNA probes built on semiconductor chips using CombiMatrix's patented technology and methods.
There are currently two classes of products derived from the CustomArray platform: CustomArrays, with user-defined DNA content, and CatalogArrays, with DNA content pre-designed by CombiMatrix.
These two classes cover the entire spectrum of customizability and convenience. Customers can define their own content, use pre-designed content, or use pre-designed content as a starting point and add or modify as they wish.
Examples of CatalogArrays include those for cancer, cholesterol metabolism, toxicology, inflammation, oxidative stress, and HIV, among many others.
"We are pleased to add CombiMatrix arrays to our portfolio of products to fulfill array needs for our customers," said Zishan Haroon, MD, Ph.D., Global Vice President, BioPharmaceuticals and BioSciences at VWR International.
"Our continuing objective is to provide an integrated array of solutions consisting of products and services to address our customer's needs.”
“CombiMatrix's CustomArray platform allows probing of client-defined target genes and works with most available scanners, providing efficient use of resources."
"This agreement significantly enhances CombiMatrix's network of distribution partnerships. It expands the reach of CustomArray technology into broader markets through VWR's worldwide sales-and-distribution channels," said Mike Tognotti, Vice President of Sales and Marketing of CombiMatrix.
"These markets include worldwide pharmaceutical and biotechnology companies as well as government and academic institutions."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.